Using a breakthrough technology, researchers led by a Weill Cornell Medical College scientist have pinpointed the hormone estrogen as a key player in about half of all prostate cancers.

An experimental drug has blocked the progression of prostate cancer in an animal model with an aggressive form of the disease, new research shows.

Modern 3-D computed tomography (CT) is an effective method for locating the prostatic apex for radiation therapy treatment planning in prostate cancer patients because it eliminates the need for an invasive procedure and the related side effects, according to a study in the May 1 issue of the International Journal of Radiation Oncology*Biology*Physics.

A re-analysis of data from the landmark Prostate Cancer Prevention Trial (PCPT) finds that finasteride reduces the risk for prostate cancer without boosting the odds of aggressive tumors.

Dynamic contrast-enhanced MRI (DCE-MRI) plus diffusion weighted imaging (DWI) can accurately diagnose residual or recurrent prostate cancer in patients treated with high-intensity focused ultrasonic ablation, a new study shows.

A comprehensive re-evaluation of the largest prostate cancer prevention study ever completed produced new findings suggesting that men and their doctors should consider a more aggressive approach that includes finasteride to prevent the development of prostate cancer.

Therapies under development to treat prostate cancer by inhibiting the ability of insulin-like growth factor (IGF-1) to activate its target receptor could have unexpected results especially if a major tumor suppressor gene – p53 – is already compromised, according to new research by investigators at Fred Hutchinson Cancer Research Center.

The expected number of deaths from prostate cancer more than halved in the Tyrol after a programme was introduced to improve early detection and treatment of the disease, according to research published in April issue of the urology journal BJU International.

Researchers at Rutgers’ Ernest Mario School of Pharmacy have shown that administering a combination of the widely used drugs Celebrex (celecoxib, a nonsteroidal anti-inflammatory drug) and Lipitor (atorvastatin, a cholesterol lowering drug) stops the transition of early prostate cancer to its more aggressive and potentially fatal stage.